ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?

Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution

ALTITUDE GROUP PLC (ALT) Equity Price and Quote

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?

Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise

Altimmune to Participate in Stifel Cardiometabolic Forum

VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune’s (ALT) Three Liver Trials Move Forward At Once

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

Keurig Dr Pepper Director Aaron Alt Buys 7,862 Shares for $250,000 -- Should Investors Buy Too?

Altimmune to discuss its liver-treatment candidate Aug. 12

Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10%

ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff